Dr. Breelyn Wilky discusses challenges that patients with GIST face and shares advice with those who feel overwhelmed by the ...

Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses; however, molecular testing can help guides treatment decisions.

Breelyn Wilky, MD, discusses what precision oncology advancements will most impact gastrointestinal stromal tumor management in the next 3 to 5 years.

Breelyn Wilky, MD, explains when patients with gastrointestinal stromal tumor should be referred for clinical trials.

Smooth muscle tumor, gastric lymphoma, tumors with a neural/neuroendocrine origin and gastrointestinal stromal tumor (GIST) were considered as potential diagnoses given the patient's presentation.

Cite this: Drug Insight: Gastrointestinal Stromal Tumors (GIST)--The Solid Tumor Model for Cancer-Specific Treatment - Medscape - Feb 01, 2008.

Multivariate analysis by Cox proportional hazards regression (Forward LR) model indicated that tumor size, mitotic rate, and risk grade were independent risk factors to OS for GISTs, and that ...

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end ...

Cogent Biosciences, Inc. is a Strong Buy after trial data for bezuclastinib & market growth potential in systemic ...

Kura Oncology's ziftomenib shows promise in AML treatment, with FDA Priority Review ahead. Read here for an analysis of KURA stock.

When most people think of cancer, names like breast, lung, or prostate cancer instantly come to mind. However, there’s another, lesser-known form called sarcoma that affects thousands of people in the ...

While cancers such as breast, lung, and prostate frequently dominate public health discussions, there is a far less recognised but equally aggressive form - sarcoma.It affects thousands across the UK ...